Table 3.

A Proposed Strategy to Assign Risk of Choledocholithiasis in Patients with Symptomatic Cholelithiasis Based on Clinical Predictors

Predictors of Choledocholithiasis
Very strong
CBD stone on TUS
Clinical ascending cholangitis
Bilirubin >4 mg/dL
Strong
Dilated CBD on TUS (>6 mm with gallbladder in situ)
Bilirubin 1.8–4 mg/dL
Moderate
Abnormal liver biochemical test not including bilirubin concentration
Age older than 55 years
Clinical gallstones pancreatitis
Assigning a likelihood of choledocholithiasis based on clinical predictors
Presence of any very strong predictor	High
Presence of both strong predictors	High
No predictors present	Low
All other patients	Intermediate

CBD, common bile duct; TUS, transabdominal ultrasonography.

Adapted from Maple et al. [22]